Quantitative projection of human brain penetration of the H₃ antagonist PF-03654746 by integrating rat-derived brain partitioning and PET receptor occupancy

Aarti Sawant-BasakDepartments of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc., Cambridge, MA, USA, Correspondence[email protected]

Laigao ChenClinical & Translational Imaging, Pfizer Inc., Cambridge, MA, USA,

Christopher L. ShafferNeuroscience and Pain Research Unit, Pfizer Inc., Cambridge, MA, USA,

Donna PalumboWorldwide Research and Development, Pfizer Inc., Cambridge, MA, USA, and

Anne SchmidtDepartments of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc., Cambridge, MA, USA,

Elaine TsengDepartments of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc., Cambridge, MA, USA,

Douglas K. SpracklinDepartments of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc., Cambridge, MA, USA,

Jean-Dominique GallezotDepartment of Diagnostic Radiology, Yale University, New Haven, CT, USA

David LabareeDepartment of Diagnostic Radiology, Yale University, New Haven, CT, USA

Nabeel NabulsiDepartment of Diagnostic Radiology, Yale University, New Haven, CT, USA

Yiyun HuangDepartment of Diagnostic Radiology, Yale University, New Haven, CT, USA

Richard E. CarsonDepartment of Diagnostic Radiology, Yale University, New Haven, CT, USA

Timothy McCarthyClinical & Translational Imaging, Pfizer Inc., Cambridge, MA, USA,

Your download is now in progress and you may close this window